Results 221 to 230 of about 6,451,411 (344)

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

open access: yesMolecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li   +10 more
wiley   +1 more source

Co-creating a decision-making framework for primary healthcare models in conflict-affected Cameroon and Nigeria. [PDF]

open access: yesBMJ Glob Health
Omam LA   +23 more
europepmc   +1 more source

Streaming Data Processing Frameworks

open access: yes, 2017
O σκοπός αυτής της πτυχιακής εργασίας είναι να αναλύσει με λεπτομέρεια τα πιο σημαντικά Πλαίσια Επεξεργασίας Συνεχούς Ροής Δεδομένων: Apache Spark, Apache Storm, Apache Flink, Apache Samza και Apache Kafka. Κάθε ένα από αυτά τα εργαλεία, είναι σχεδιασμένο με έναν ξεχωριστό τρόπο, ωστόσο κάθε ένα από αυτά χρησιμοποιείται για τον ίδιο σκοπό: επεξεργασία ...
openaire   +1 more source

Infrared laser sampling of low volumes combined with shotgun lipidomics reveals lipid markers in palatine tonsil carcinoma

open access: yesMolecular Oncology, EarlyView.
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff   +11 more
wiley   +1 more source

Operationalizing systemic multi-hazard and multi-risk assessment: Lessons from the MYRIAD-EU framework. [PDF]

open access: yesiScience
Hochrainer-Stigler S   +26 more
europepmc   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

open access: yesMolecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy